Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI ...

For the first time, people with bronchiectasis will have a treatment option. The U.S. Food and Drug Administration (FDA) has ...

The U.S. Food and Drug Administration has approved Insmed's daily bronchiectasis pill, brensocatib, which will be sold under the brand name Brinsupri.

A new federal study is linking the ability to quit smoking with longer-term success from the grip of drug or alcohol ...

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and ...

The Food and Drug Administration (FDA) has approved Brinsupri ™ (brensocatib) for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adult and pediatric patients aged 12 years and older.